Mood Disorders

Sustained Benefits of Zuranolone in Patients With Major Depressive Disorder: Results From the LANDSCAPE Clinical Development Program

Abstract: Introduction Many patients with major depressive disorder (MDD) experience relapse after responding to standard-of-care antidepressants. Zuranolone is a neuroactive steroid and ...

Zehra Gundogan ;

Manny Garcia ;

01/19/2023

Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (Dextromethorphan-Bupropion), an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double-Blind, Controlled Trials

Abstract: Background: AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorpha...

Zachariah Thomas , DPM, AACFAS;

William Olsufka , PharmD;

01/19/2023

AXS-05 (Dextromethorphan-Bupropion) Improves Depressive Symptoms and Functioning in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study

Abstract: Background: In STAR*D, following non-remission with an SSRI, remission rates for second line treatments were ~ 25% regardless of the switch strategy employed. Antidepressants ...

Matthew J. Baker , PharmD;

Zachariah Thomas , DPM, AACFAS;

01/19/2023

Improving Patient Outcomes with the PHQ-9 in a Longitudinal Sample of Psychiatric Inpatients

Abstract: This study investigated the implementation of depression screening with the Patient Health Questionnaire (PHQ-9) in inpatient psychiatric care in a tri-state hospital group, Oce...

Marcell Gary ;

Julie Jeter ;

01/19/2023

Improvement in Anxiety Symptoms in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-label, Long-term Study

Abstract: Background: Innovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed. AXS-05 (dextromethorphan HBr 45 mg- bupropion HCl...

Shawn Alter , PhD;

Zachariah Thomas , DPM, AACFAS;

01/19/2023

Safety, Tolerability, and Efficacy of Zuranolone Repeat Treatment Courses in Adult Patients With Major Depressive Disorder–An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Rapid response and episodic treatment potential are important in the treatment of major depressive disorder (MDD). Zuranolone is a neuroactive steroid and positive ...

Ramon Iovine ;

Zehra Gundogan ;

01/19/2023

Studying the Impact of Patient Treatment Experiences on Patient Hope for Major Depressive Disorder Pharmacotherapies

Abstract: Background: Individuals receiving treatment for major depressive disorder (MDD) continue to face multiple disease or treatment-related issues. A web-based survey was conducted w...

Shawn Alter , PhD;

Iresha Abeynayake ;

01/19/2023

Efficacy and Safety of Zuranolone in Adults With Major Depressive Disorder With and Without Use of Standard-of-Care Antidepressants at Baseline in the LANDSCAPE Clinical Development Program

Abstract: Introduction Zuranolone is a neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an oral, once-daily, ...

Coleville Brown ;

Zehra Gundogan ;

01/19/2023

Safety and Tolerability of Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 2B and 3 Clinical Trials

Abstract: Background: Safety of cariprazine in patients with major depressive disorder (MDD) with inadequate response to antidepressants was evaluated. Methods: Safety, tolerability, and ...

Claudia Berger ;

Marco Viscomi ;

01/19/2023

Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301)

Abstract: Background: Patients with MDD often do not respond to antidepressant (ADT) monotherapy. Cariprazine (CAR) is under investigation as adjunctive therapy for patients with MDD. M...

Cara Lutzow ;

Claudia Berger ;

01/19/2023